Page 11234..1020..»

PAOG Announces Pending Acquisition To Expand CBD IP Portfolio Scheduled For Early December

By Dr. Matthew Watson

Sandusky, OH, Nov. 19, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company has finalized terms for the acquisition of a license to a patented cannabis extraction process that will expand the company’s existing CBD intellectual property.

Read the original post:
PAOG Announces Pending Acquisition To Expand CBD IP Portfolio Scheduled For Early December

To Read More: PAOG Announces Pending Acquisition To Expand CBD IP Portfolio Scheduled For Early December
categoriaGlobal News Feed commentoComments Off on PAOG Announces Pending Acquisition To Expand CBD IP Portfolio Scheduled For Early December | dataNovember 22nd, 2021
Read All

T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement

By Dr. Matthew Watson

LEXINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.

See more here:
T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement

To Read More: T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement
categoriaGlobal News Feed commentoComments Off on T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement | dataNovember 22nd, 2021
Read All

Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

By Dr. Matthew Watson

Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer Primary results from ONAWA (SOLTI-1802) trial of ONA-XR in early breast cancer to be presented in addition to updates from ongoing clinical trials of ONA-XR in metastatic breast cancer

Follow this link:
Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium

To Read More: Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium
categoriaGlobal News Feed commentoComments Off on Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer Symposium | dataNovember 22nd, 2021
Read All

European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

By Dr. Matthew Watson

Basel, 19 November 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) has granted conditional marketing authorisation for Gavreto® (pralsetinib) as a monotherapy for the treatment of adults with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. Gavreto is the first and only precision medicine approved in the European Union (EU) for the first-line treatment of people with RET fusion-positive advanced NSCLC.1

More:
European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

To Read More: European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer
categoriaGlobal News Feed commentoComments Off on European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer | dataNovember 22nd, 2021
Read All

Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast…

By Dr. Matthew Watson

NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose escalation trial of ARV-471, a novel oral estrogen receptor (ER)-targeting PROteolysis TArgeting Chimera (PROTAC®) protein degrader, will be presented in a spotlight poster-discussion session at the 2021 San Antonio Breast Cancer Symposium (SABCS) on December 7-10, 2021. ARV-471 is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Original post:
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast...

To Read More: Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast…
categoriaGlobal News Feed commentoComments Off on Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast… | dataNovember 22nd, 2021
Read All

Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

By Dr. Matthew Watson

Nicosia, Cyprus, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) reports that PJSC Kraspharma at the end of 2020 entered the TOP-5 of the most dynamic and largest pharmaceutical companies in Russia for 2020, showing incredible growth rates with a net profit increase of 220.9% compared to 2019. Specifically, Kraspharma went from $5,563,056 (USD) at the end of 2019 to $17,853,905 at the end of 2020. The growth was featured in the ratings by the authoritative Russian industry publication "Remedium", published in Q3 of 2021.

More:
Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5

To Read More: Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5
categoriaGlobal News Feed commentoComments Off on Explosive Growth Launches Kraspharma Into REMEDIUM TOP-5 | dataNovember 22nd, 2021
Read All

Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

By Dr. Matthew Watson

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference.

Read the rest here:
Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference

To Read More: Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Vor to Participate in Piper Sandler 33rd Virtual Annual Healthcare Conference | dataNovember 22nd, 2021
Read All

Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

By Dr. Matthew Watson

SAN DIEGO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it will host an investor conference call on Monday, November 22, 2021 at 2 p.m. Pacific Time to discuss its financial and operating results for the first nine months of 2021, as well as provide a business update. The Company’s press release concerning its financial results will be available after 1 p.m. Pacific Time on November 22, 2021 and on its website at www.adamispharmaceuticals.com, and the company also expects to file its quarterly reports on Form 10-Q for the quarters ended March 31, 2021, June 30, 2021 and September 30, 2021 on that date.

View original post here:
Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update

To Read More: Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
categoriaGlobal News Feed commentoComments Off on Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update | dataNovember 22nd, 2021
Read All

Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

By Dr. Matthew Watson

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021.

Read more:
Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference

To Read More: Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Sensei Biotherapeutics to Participate in the Piper Sandler 33rd Annual Healthcare Conference | dataNovember 22nd, 2021
Read All

Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee.

Visit link:
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataNovember 22nd, 2021
Read All

PacBio Grants Equity Incentive Award to New Employee

By Dr. Matthew Watson

MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on November 15, 2021.

See the rest here:
PacBio Grants Equity Incentive Award to New Employee

To Read More: PacBio Grants Equity Incentive Award to New Employee
categoriaGlobal News Feed commentoComments Off on PacBio Grants Equity Incentive Award to New Employee | dataNovember 22nd, 2021
Read All

Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

By Dr. Matthew Watson

NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2021 and provided an update on Acer’s recent corporate developments.

See the original post:
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update

To Read More: Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
categoriaGlobal News Feed commentoComments Off on Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update | dataNovember 22nd, 2021
Read All

Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter

By Dr. Matthew Watson

TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a default status report in accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”) and disclosing receipt of a Nasdaq Listing delinquency letter.

Read the rest here:
Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter

To Read More: Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter
categoriaGlobal News Feed commentoComments Off on Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter | dataNovember 22nd, 2021
Read All

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

By Dr. Matthew Watson

SAN CARLOS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on November 18, 2021 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 168,575 shares of Iovance’s common stock to seven new non-executive employees.

Originally posted here:
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

To Read More: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | dataNovember 22nd, 2021
Read All

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

By Dr. Matthew Watson

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products

Read more:
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

To Read More: Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
categoriaGlobal News Feed commentoComments Off on Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor | dataNovember 22nd, 2021
Read All

Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

By Dr. Matthew Watson

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).

Read more:
Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility

To Read More: Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility
categoriaGlobal News Feed commentoComments Off on Mesoblast and Oaktree Capital Enter Into Refinancing and Expansion of Senior Debt Facility | dataNovember 22nd, 2021
Read All

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

By Dr. Matthew Watson

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Link:
Obseva Announces Appointment of Stephanie Brown to its Board of Directors

To Read More: Obseva Announces Appointment of Stephanie Brown to its Board of Directors
categoriaGlobal News Feed commentoComments Off on Obseva Announces Appointment of Stephanie Brown to its Board of Directors | dataNovember 22nd, 2021
Read All

Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt

By Dr. Matthew Watson

VANCOUVER, British Columbia, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Agra Ventures Ltd. (“AGRA” or the “Company”) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: AGFAF), a growth-oriented and diversified company focused on the international cannabis industry, announces that its Board of Directors has approved the Company’s issuance of 8,744 common shares (the “Shares”) at a deemed price of $0.84 per Share as payment of the portion of the quarterly amount of interest due in Shares on a loan entered into in December of 2020. All Shares issued will be subject to a minimum hold period of four months and one day from the date of issuance.

Read more:
Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt

To Read More: Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt
categoriaGlobal News Feed commentoComments Off on Agra Ventures Issues Shares as Regular Payment of Partial Amount of Interest on Debt | dataNovember 22nd, 2021
Read All

OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

By Dr. Matthew Watson

Provides Additional Capital to further Develop the Company’s Innovative Pipeline of Novel Clinical Assets, THR-687 and THR-149

Read the original:
OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures

To Read More: OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures
categoriaGlobal News Feed commentoComments Off on OXURION NV Secures EUR 10 Million Convertible Bond Financing from Kreos Capital and Pontifax Ventures | dataNovember 22nd, 2021
Read All

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

By Dr. Matthew Watson

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Read more here:
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

To Read More: Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
categoriaGlobal News Feed commentoComments Off on Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix | dataNovember 22nd, 2021
Read All

Page 11234..1020..»